Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL515728 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AFFAR4FFAR1 | |
| SCHEMBL15977917 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AFFAR4FFAR1 | |
| SCHEMBL7914906 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AFFAR4FFAR1 | |
| SCHEMBL788641 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AFFAR4FFAR1 | |
| SCHEMBL25206528 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AFFAR4FFAR1 | |
| SCHEMBL198354 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AFFAR4FFAR1 | |
| SCHEMBL23234144 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AFFAR4FFAR1 | |
| SCHEMBL23016820 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AFFAR4FFAR1 | |
| SCHEMBL61278 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AFFAR4FFAR1 | |
| SCHEMBL31314689 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AFFAR4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4637720-A1 | PROCESS FOR PREPARING STABLE NANOPARTICLE AND COMPOSITION THEREOF | Nanomi B.V. (NL) | 2025-10-29 | — | — | EP | claimed |
| WO-2024136660-A1 | PROCESS FOR PREPARING STABLE NANOPARTICLE AND COMPOSITION THEREOF | NANOMI B.V. (NL) | 2024-06-27 | — | — | WO | claimed |
| WO-2023085323-A1 | METHOD FOR REDUCING MEASUREMENT ERRORS DUE TO HEMOLYZED HEMOGLOBIN | 東洋紡株式会社 | 2023-05-19 | — | — | WO | claimed |
| CN-115777065-A | Compositions containing TARC and methods for improving the storage stability of TARC | 积水医疗株式会社 | 2023-03-10 | — | — | CN | claimed |
| WO-2022043829-A1 | PFAS REMEDIATION | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2022-03-03 | — | — | WO | claimed |
| WO-2025136359-A1 | ENDOBRONCHIAL DRUG COATED BALLOON | BARD PERIPHERAL VASCULAR, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025122719-A1 | DIALYSIS-BASED METHOD FOR AFFINITY MAPPING OF CHROMATIN INTERACTIONS | CZ BIOHUB SF, LLC (US) | 2025-06-12 | — | — | WO | disclosed |
| WO-2024263155-A1 | PROTECTIVE COVERINGS FOR DRUG COATED BALLOONS | BARD PERIPHERAL VASCULAR, INC. (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024242668-A1 | PROTECTIVE COVERINGS FOR DRUG COATED BALLOONS | BARD PERIPHERAL VASCULAR, INC. (US) | 2024-11-28 | — | — | WO | disclosed |
| US-20240376292-A1 | COMPOSITIONS AND METHODS FOR REMOVING BORON FROM AQUEOUS SOLUTIONS | CARBONET NANOTECHNOLOGIES INC. (CA) | 2024-11-14 | — | — | US | disclosed |
| WO-2024191445-A1 | THERAPEUTIC BIO-ABSORBABLE POLYMERIC SCAFFOLD WITH DRUG-LOADED MICRO-NEEDLES FOR DRUG DELIVERY | BECTON, DICKINSON AND COMPANY (US) | 2024-09-19 | — | — | WO | disclosed |
| EP-4408495-A1 | A DRUG COATING FORMULATION FOR A SIROLIMUS COATED BALLOON CATHETER | C. R. Bard, Inc. (US) | 2024-08-07 | — | — | EP | disclosed |
| WO-2019177157-A1 | REAGENT KIT, MEASUREMENT KIT, AND MEASUREMENT METHOD | 富士フイルム株式会社 | 2019-09-19 | — | — | WO | disclosed |
| US-20190117798-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2019-04-25 | — | — | US | disclosed |
| US-20190110472-A1 | ACTIVE INGREDIENT COMPOSITIONS COMPRISING N-ALKENOYL-N-ALKYLGLUCAMIDES AND THE USE THEREOF | CLARIANT INTERNATIONAL, LTD. (CH) | 2019-04-18 | — | — | US | disclosed |
| US-10207010-B2 | Compositions and methods for delivery of agents | MODERNATX, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180147298-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180028664-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2018-02-01 | — | — | US | disclosed |
| US-20170339949-A1 | SUGAR SURFACTANTS AND USE THEREOF IN AGROCHEMICAL COMPOSITIONS | CLARIANT INTERNATIONAL LTD. (CH) | 2017-11-30 | — | — | US | disclosed |
| WO-2017099823-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190117798-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | HDLBP, APOB, TSG101 | EPHX2 2965/4885MEN1 3349/4885KMT2A 3137/4885 |
| US-20190110472-A1 | ACTIVE INGREDIENT COMPOSITIONS COMPRISING N-ALKENOYL-N-ALKYLGLUCAMIDES AND THE USE THEREOF | B3GNT2, GANAB, GBA2 | EPHX2 971/4885MEN1 3065/4885KMT2A 1273/4885 |
| US-10207010-B2 | Compositions and methods for delivery of agents | HDLBP, APOB, TSG101 | EPHX2 2965/4885MEN1 3349/4885KMT2A 3137/4885 |
| US-20170339949-A1 | SUGAR SURFACTANTS AND USE THEREOF IN AGROCHEMICAL COMPOSITIONS | SGMS1, DEGS1, SGMS2 | EPHX2 447/4885MEN1 2633/4885KMT2A 2459/4885 |
| US-20180147298-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | HDLBP, APOB, TSG101 | EPHX2 2965/4885MEN1 3349/4885KMT2A 3137/4885 |
| US-20180028664-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | HDLBP, APOB, TSG101 | EPHX2 2965/4885MEN1 3349/4885KMT2A 3137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.